Clinical trial
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
NCT02717949 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
- Lead sponsor
- University of Texas Southwestern Medical Center
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- February 25, 2016
- Completion date
- July 18, 2017
- Enrollment
- 1 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
liver disease